Skip to main content

News and blog posts

16
May 2022

Recommendations about add-on reimbursement for medical devices in France in April 2022

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in April 2022. Thirty recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular and peripheral vascular, orthopedic, neurovascular, and neuromodulation and other devices, as well as medical aids.
10
May 2022

Genetic test to prevent child deafening being implemented in England

A new test called Genedrive System to detect babies at risk of gentamycin-related deafness was developed at the University of Manchester, funded by the National Institute for Health and Care Research (NIHR). On April 02, 2022, NHS England and NHS Improvement announced that Genedrive is now fully CE certified to be used in a clinical setting. The test is expected to be implemented in routine care in all NHS Manchester Foundation Trust hospitals within several weeks.
06
May 2022

Published health technology assessments in Wales in Q1 of 2022

In Q1 of 2022, Health Technology Wales (HTW) published one MedTech-related guidance on transcranial magnetic stimulation in depression treatment. A total of eleven Topic Exploration Reports (TERs) were released in Q1. Based on the TERs conclusions, HTW's Assessment Group decided to proceed with developing an Evidence Appraisal Report (EAR) and Guidance on one topic only - radiofrequency renal denervation for the treatment of resistant hypertension.
05
May 2022

Three more health apps obtained reimbursement in Germany

In March and April 2022, three more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, thirty-three health apps are now available at the DiGA Directory.
03
May 2022

2022/23 NHS priorities and operational planning guidance in England

On April 12, 2022, NHS England and NHS Improvement (NHSE/I) published 2022/23 priorities and operational planning guidance, including elective recovery planning supporting guidance, capital guidance for 2022-25, and revenue finance and contracting guidance. The 2022/23 priorities and operational planning guidance set out NHSE/I priorities for the year ahead and reconfirms the ongoing need to restore services, meet new care demands, and reduce the care backlogs that are a direct consequence of the pandemic.